Monte Rosa Therapeutics Reports Q2 2026 Financial Results

What Happened

• Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) filed a Form 8‑K on August 6, 2026 to announce its financial results for the quarter ended June 30, 2026. The company furnished the full press release with those quarterly results as Exhibit 99.1 to the filing. The report was signed by Markus Warmuth, President and Chief Executive Officer.

Key Details

• Filing date: August 6, 2026 (Form 8‑K, Item 2.02: Results of Operations and Financial Condition).
• Reporting period: Quarter ended June 30, 2026 (quarterly results / earnings announcement).
• Press release with the detailed results is furnished as Exhibit 99.1 to the 8‑K.
• Filing was executed by Markus Warmuth, President and CEO.

Why It Matters

• This 8‑K is the company’s official disclosure of its latest quarterly results; investors should review the Exhibit 99.1 press release to see revenue, expenses, net loss, cash position and any guidance or operational updates. Quarterly earnings disclosures can materially affect stock price and investor assessments of Monte Rosa’s financial health and runway. This filing does not report any management changes or other material corporate actions beyond the earnings release.